loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Open ICICI
3-in-1 Account

Manage your Savings, Demat and Trading Account conveniently at one place

+91

BLOG

Aurobindo Pharma subsidiary Acrotech Biopharma has launched ADQUEY (difamilast 1%) ointment in the US

ICICIdirect Research 01 Oct 2026 DISCLAIMER

News: Aurobindo Pharma subsidiary Acrotech Biopharma has launched ADQUEY (difamilast 1%) ointment in the US for mild-to-moderate atopic dermatitis in adults and pediatric patients aged 2 years and above. The non-steroidal topical PDE4 inhibitor, originally discovered by Otsuka Pharmaceutical, addresses a US market estimated at ~US$1.3 billion as per IQVIA MAT July 2026. Aurobindo has also established a dedicated dermatology business unit to support commercialization and patient access, marking Acrotech Biopharma entry into the US dermatology market.

View: Given the differentiated nature of the product (Specialty product) and limited competition, we believe ADQUEY presents a potentially meaningful opportunity for Aurobindo Pharma, particularly from a profitability perspective even after considering milestone and other related payments. We expect to get further clarity on the product’s commercial potential, margin profile and associated milestone obligations from management during the upcoming earnings calls.

Impact: Positive

Download
ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download
ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere